Evidence map›Paper›PMID 27187154›Full record

ArticleJournal of cellular physiology2016

AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication.

Laurence Booth, Jane L Roberts, Heath Ecroyd, Sarah R Tritsch, Sina Bavari, St Patrick Reid, Stefan Proniuk, Alexander Zukiwski, Abraham Jacob, Claudia S Sepúlveda and 6 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of cellular physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Article
  5. Review
  6. New Therapeutic Modalities in Prion Diseases.Sub-cellular biochemistry · 2025
    Review
  7. Article
  8. COVID-19, Obesity, and GRP78: Unraveling the Pathological Link.Journal of obesity & metabolic syndrome · 2023
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Laurence BoothDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.
Jane L RobertsDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.
Heath EcroydSchool of Biological Sciences and Illawarra Health and Medical Research Institute, University of Wollongong, New South Wales, Australia.
Sarah R TritschMolecular and Translational Science, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, Maryland.
Sina BavariMolecular and Translational Science, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, Maryland.
St Patrick ReidMolecular and Translational Science, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, Maryland.
Stefan ProniukArno Therapeutics, Flemington, New Jersey.
Alexander ZukiwskiArno Therapeutics, Flemington, New Jersey.
Abraham JacobDepartment of Otolaryngology, University of Arizona Ear Institute, Tucson, Arizona.
Claudia S SepúlvedaFCEN-UBA, Ciudad Universitaria, Pabellón 2 Piso 4, lab QB-17, Buenos Aires, Argentina.
Federico GiovannoniFCEN-UBA, Ciudad Universitaria, Pabellón 2 Piso 4, lab QB-17, Buenos Aires, Argentina.
Cybele C GarcíaFCEN-UBA, Ciudad Universitaria, Pabellón 2 Piso 4, lab QB-17, Buenos Aires, Argentina.
Elsa DamonteFCEN-UBA, Ciudad Universitaria, Pabellón 2 Piso 4, lab QB-17, Buenos Aires, Argentina.
Javier González-GallegoInstitute of Biomedicine and CIBEREhd, University of León, León, Spain.
María J TuñónInstitute of Biomedicine and CIBEREhd, University of León, León, Spain.
Paul DentDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.
United States Army Medical Research Institute of Infectious Diseases · USVirginia Commonwealth University · USArno Therapeutics (United States) · USUniversidad de León · ESUniversity of Arizona · USUniversity of Wollongong · AU

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Pemetrexed and sildenafil for lung cancerR01CA192613 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DENT, PAUL · 2015 to 2019
$1.6M
NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA192613NIAID NIH HHS HHSN272201300010I
6 · The paper itself

Abstract

We have recently demonstrated that AR-12 (OSU-03012) reduces the function and ATPase activities of multiple HSP90 and HSP70 family chaperones. Combined knock down of chaperones or AR-12 treatment acted to reduce the expression of virus receptors and essential glucosidase proteins. Combined knock down of chaperones or AR-12 treatment inactivated mTOR and elevated ATG13 S318 phosphorylation concomitant with inducing an endoplasmic reticulum stress response that in an eIF2α-dependent fashion increased Beclin1 and LC3 expression and autophagosome formation. Over-expression of chaperones prevented the reduction in receptor/glucosidase expression, mTOR inactivation, the ER stress response, and autophagosome formation. AR-12 reduced the reproduction of viruses including Mumps, Influenza, Measles, Junín, Rubella, HIV (wild type and protease resistant), and Ebola, an effect replicated by knock down of multiple chaperone proteins. AR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78. Knock down of Beclin1 suppressed drug-induced autophagosome formation and reduced the anti-viral protection afforded by AR-12. In an animal model of hemorrhagic fever virus, a transient exposure of animals to low doses of AR-12 doubled animal survival from ∼30% to ∼60% and suppressed liver damage as measured by ATL, GGT and LDH release. Thus through inhibition of chaperone protein functions; reducing the production, stability and processing of viral proteins; and stimulating autophagosome formation/viral protein degradation, AR-12 acts as a broad-specificity anti-viral drug in vitro and in vivo. We argue future patient studies with AR-12 are warranted. J. Cell. Physiol. 231: 2286-2302, 2016. © 2016 Wiley Periodicals, Inc.

Indexed as

AutophagosomesAutophagyCell LineEndoplasmic ReticulumEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressHumansMolecular ChaperonesPyrazolesSulfonamidesVirus ReplicationEndoplasmic Reticulum Chaperone BiPHSPA5 protein, humanMolecular ChaperonesOSU 03012PyrazolesSulfonamides

Identifiers

PMID27187154
PMCPMC6327852
OpenAlexW2399723778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.